Company intelligence / Profile preview

Jexys Pharmaceuticals

Jerusalem, Israel

Ownership: Private
Development stage: Other

Overview

Jexys developed a proprietary cell-based drug discovery platform using yeast cells engineered to express mutated proteins associated with human diseases. The platform enables rapid screening of thousands of candidate drugs at reduced cost and time compared to traditional methods. The company isolated novel molecules targeting p38 for inflammatory conditions, which were verified to be non-cytotoxic, membrane-permeable, and specific.

Therapeutic areas: OncologyImmunologyNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Teva Pharmaceutical Industries (strategic R&D collaboration agreement signed December 2008, extending an earlier October 2006 agreement)

Beyond the preview

Go deeper on Jexys Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jexys Pharmaceuticals.

Explore the full profile